Diabetic retinopathy(DR)is the most common cause of visual loss among working age *** macular edema(DME)is an important complication of DR that affects around one third of the patients with *** treatments have been ap...
详细信息
Diabetic retinopathy(DR)is the most common cause of visual loss among working age *** macular edema(DME)is an important complication of DR that affects around one third of the patients with *** treatments have been approved for DME ranging from blood pressure and glycemic control to photocoagulation and more recently the use of vascular endothelial growth factor(VEGF)*** index review discusses aflibercept(EYLEA-Regeneron Pharmaceuticals,Inc.,Tarrytown,New York,NY,and Bayer Healthcare Pharmaceuticals,Berlin,Germany)in the context of other VEGF antagonists currently available for the treatment of DME.A systematic search of literature was conducted on PubMed,Scopus,and Google Scholar with no limitation on language or year of ***-clinical studies of aflibercept have shown a higher affinity of this molecule for vascular endothelial growth factor A(VEGF-A)along with a longer duration of action as compared to other VEGF *** clinical trials have shown visual outcome results for aflibercept to be similarly favorable as compared to other available agents with the added benefit of fewer required injections and less frequent *** presents a potential exciting new addition to the armamentarium of current VEGF antagonists available for the treatment of DME and other retinal vascular ***,further studies are indicated to confirm the role,safety,and efficacy of aflibercept for DME.
暂无评论